COST-UTILITY ANALYSIS OF ADJUVANT PERTUZUMAB-BASED REGIMEN IN WOMEN WITH HER2-POSITIVE BREAST CANCER IN ITALY

被引：1
|
作者：
Pradelli, L. [1 ]
Zaniolo, O. [1 ]
Caputo, A. [2 ]
Roussel, M. [3 ]
Tournier, C. [3 ]
机构：
[1] AdRes HEOR, Turin, Italy
[2] Roche SpA, Monza, Italy
[3] F Hoffmann La Roche & Cie AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.264
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN181
引用
收藏
页码：S45 / S45
页数：1
相关论文
共 50 条
  • [1] Is there a role for adjuvant pertuzumab in HER2-positive breast cancer?
    Mazzotta, Marco
    Barba, Maddalena
    Pizzuti, Laura
    Vici, Patrizia
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S281 - S284
  • [2] Cost-utility analysis of lapatinib in treatment of HER2-positive advanced breast cancer
    Le, Q. A.
    Hay, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Anne Julienne Genuino
    Usa Chaikledkaew
    Anna Melissa Guerrero
    Thanyanan Reungwetwattana
    Ammarin Thakkinstian
    BMC Health Services Research, 19
  • [4] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Genuino, Anne Julienne
    Chaikledkaew, Usa
    Guerrero, Anna Melissa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (01)
  • [5] Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis
    Leung, William
    Kvizhinadze, Giorgi
    Nair, Nisha
    Blakely, Tony
    PLOS MEDICINE, 2016, 13 (08):
  • [6] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [7] COST-UTILITY ANALYSIS OF TRASTUZUMAB IN TREATMENT OF METASTATIC HER2-POSITIVE BREAST CANCER IN VIETNAM
    Nguyen, T. T. C.
    Nguyen, T. T. T.
    VALUE IN HEALTH, 2014, 17 (07) : A643 - A643
  • [8] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [9] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
  • [10] Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Iyengar, N. M.
    Smyth, L. M.
    Lake, D.
    Gucalp, A.
    Singh, J. C.
    Traina, T. A.
    Defusco, P.
    Dickler, M. N.
    Fornier, M. N.
    Goldfarb, S. B.
    Jhaveri, K.
    Modi, S.
    Troso-Sandoval, T.
    Jack, K.
    Ulaner, G.
    Jochelson, M.
    Baselga, J.
    Norton, L.
    Hudis, C. A.
    Dang, C. T.
    ANNALS OF ONCOLOGY, 2017, 28
12345